BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 29966295)

  • 1. Regulation of CYP2J2 and EET Levels in Cardiac Disease and Diabetes.
    Aliwarga T; Evangelista EA; Sotoodehnia N; Lemaitre RN; Totah RA
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29966295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance.
    Xu M; Ju W; Hao H; Wang G; Li P
    Drug Metab Rev; 2013 Aug; 45(3):311-52. PubMed ID: 23865864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac Disease Alters Myocardial Tissue Levels of Epoxyeicosatrienoic Acids and Key Proteins Involved in Their Biosynthesis and Degradation.
    Aliwarga T; Dinh JC; Heyward S; Prasad B; Gharib SA; Lemaitre RN; Sotoodehnia N; Totah RA
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2J2
    Tao P; Jiang Y; Wang H; Gao G
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):932-941. PubMed ID: 34707002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes.
    Leow JWH; Gu Y; Chan ECY
    Eur J Pharm Sci; 2023 Aug; 187():106475. PubMed ID: 37225005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical kinetics of cytochrome P450 2J2: Epoxidation of arachidonic acid and reversible inhibition by xenobiotic inhibitors.
    Leow JWH; Verma RK; Lim ABH; Fan H; Chan ECY
    Eur J Pharm Sci; 2021 Sep; 164():105889. PubMed ID: 34044117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2J2 metabolites, epoxyeicosatrienoic acids, attenuate Ang II-induced cardiac fibrotic response by targeting Gα
    He Z; Yang Y; Wen Z; Chen C; Xu X; Zhu Y; Wang Y; Wang DW
    J Lipid Res; 2017 Jul; 58(7):1338-1353. PubMed ID: 28554983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2.
    Spiecker M; Darius H; Hankeln T; Soufi M; Sattler AM; Schaefer JR; Node K; Börgel J; Mügge A; Lindpaintner K; Huesing A; Maisch B; Zeldin DC; Liao JK
    Circulation; 2004 Oct; 110(15):2132-6. PubMed ID: 15466638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of cytochrome P450-epoxygenase and soluble epoxide hydrolase in the regulation of vascular response.
    Nayeem MA; Geldenhuys WJ; Hanif A
    Adv Pharmacol; 2023; 97():37-131. PubMed ID: 37236764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.
    Xu X; Zhang XA; Wang DW
    Adv Drug Deliv Rev; 2011 Jul; 63(8):597-609. PubMed ID: 21477627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth.
    Chen C; Wei X; Rao X; Wu J; Yang S; Chen F; Ma D; Zhou J; Dackor RT; Zeldin DC; Wang DW
    J Pharmacol Exp Ther; 2011 Feb; 336(2):344-55. PubMed ID: 21030485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2J2 attenuates metabolic dysfunction in diabetic mice by reducing hepatic inflammation via the PPARγ.
    Li R; Xu X; Chen C; Wang Y; Gruzdev A; Zeldin DC; Wang DW
    Am J Physiol Endocrinol Metab; 2015 Feb; 308(4):E270-82. PubMed ID: 25389363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Epoxyeicosatrienoic Acids in Cardiac Remodeling.
    Lai J; Chen C
    Front Physiol; 2021; 12():642470. PubMed ID: 33716791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating the association between CYP2J2 inhibitors and QT prolongation: a literature review.
    Wiley AM; Yang J; Madhani R; Nath A; Totah RA
    Drug Metab Rev; 2024; 56(2):145-163. PubMed ID: 38478383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450 Epoxygenase 2J2 Protects Against Lung Ischemia/Reperfusion Injury by Activating the P13K/Akt/GSK-3-β/NF-kB Signaling Pathway During Deep Hypothermic Low Flow in Mice.
    Yang Y; Wang J; Peng W; Shu Y; Mo X
    J Surg Res; 2020 Sep; 253():8-17. PubMed ID: 32305498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2J2 Expression in Adult Ventricular Myocytes Protects Against Reactive Oxygen Species Toxicity.
    Evangelista EA; Lemaitre RN; Sotoodehnia N; Gharib SA; Totah RA
    Drug Metab Dispos; 2018 Apr; 46(4):380-386. PubMed ID: 29343610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2J2 and EETs protect against pulmonary arterial hypertension with lung ischemia-reperfusion injury in vivo and in vitro.
    Ding Y; Tu P; Chen Y; Huang Y; Pan X; Chen W
    Respir Res; 2021 Nov; 22(1):291. PubMed ID: 34774051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2J2 and its metabolites (epoxyeicosatrienoic acids) attenuate cardiac hypertrophy by activating AMPKα2 and enhancing nuclear translocation of Akt1.
    Wang B; Zeng H; Wen Z; Chen C; Wang DW
    Aging Cell; 2016 Oct; 15(5):940-52. PubMed ID: 27416746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of multi-kinase inhibitors on the activity of cytochrome P450 2J2.
    Kojima A; Nadai M; Murayama N; Yamazaki H; Katoh M
    Xenobiotica; 2022 Jul; 52(7):669-675. PubMed ID: 36251932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variation in the G-50T polymorphism of the cytochrome P450 epoxygenase CYP2J2 gene and the risk of younger onset type 2 diabetes among Chinese population: potential interaction with body mass index and family history.
    Wang CP; Hung WC; Yu TH; Chiu CA; Lu LF; Chung FM; Hung CH; Shin SJ; Chen HJ; Lee YJ
    Exp Clin Endocrinol Diabetes; 2010 Jun; 118(6):346-52. PubMed ID: 20140850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.